The Globe and Mail reports in its Tuesday, April 24, edition that RBC analyst Douglas Miehm says Knight Therapeutics ($8.14) presents investors with an attractive risk-reward proposition. The Globe's David Leeder writes in the Eye On Equities column that Mr. Miehm recommends Knight Therapeutics for investors seeking long-term price appreciation. Mr. Miehm began coverage of the Montreal-based pharmaceuticals company with an "outperform" rating. Mr. Miehm set a share target of $9.50. Analysts on average target the shares at $9.43. Mr. Miehm says in a note: "Knight was formed in 2014 as a carve-out of Paladin Labs when it was acquired by Endo International for $3.2-billion. Like Paladin, Knight's focus is on the licensing and acquisition of late-stage pharma products for Canada and select international markets. Knight's CEO Jonathan Goodman led Paladin through a decade of revenue and EBITDA growth (compounded) 30 per cent annually, with shares going from $2.30 to $142.06 following its acquisition. With the same strategy being employed at Knight, we see strong potential for repeated success over the mid- to long-term. ... We believe downside is limited as it is unlikely that shares trade below book value."
© 2024 Canjex Publishing Ltd. All rights reserved.